Male Infertility Market Report

Male Infertility Market Analysis By Test (DNA Fragmentation Technique, Oxidative Stress Analysis, Microscopic Examination, Sperm Agglutination, Sperm Penetration Assay), By Treatment, And Segment Forecasts, 2018 - 2025

  • Published Date: May, 2017
  • Base Year for Estimate: 2016
  • Report ID: GVR-1-68038-833-6
  • Format: Electronic (PDF)
  • Historical Data: 2014 - 2016
  • Number of Pages: 100

Industry Insights

The global male infertility market size was estimated at around USD 3 billion in 2016. Globally, increasing infertility rate and adoption of Assisted Reproductive Technologies (ART) are expected to be key factors driving the market growth.

Increasing demand of ART is a major cause of the globally rising male infertility industry revenue. ARTs offer helps to male with no sperm, abnormal sperm, or sperm with poor motility. Furthermore, high success rate as compared to medication and advancements in technology is expected to increase the demand in the near future, which drives the market growth.

U.S. male infertility market by test, 2014-2025 (USD Million)

U.S. male infertility market

Rising cases of infertility across the globe is a significant clinical problem. Globally, 8%to12% of couples are affected with infertility worldwide. Of all cases, about 40% to 50% cases were due to male factor. This may be due to one or more factors such as poor sperm motility, lower sperm concentration, and abnormal morphology. Hence, increasing male infertility and awareness about the same has further prompted the use of drugs, hormonal therapy, and ART. 

There are continuous efforts in R&D for better understanding of idiopathic world of infertility. Hence, companies are investing in the development of devices for identifying the root cause and targeted treatment. Furthermore, development and commercialization of hormonal therapy is likely to drive the market during the forecast period.

Test Insights

Male infertility can be diagnosed with DNA fragmentation technique, oxidative stress analysis, microscopic examination, sperm agglutination, Computer-Assisted Semen Analysis (CASA), sperm penetration assay, and some other techniques.

DNA fragmentation accounted for the largest segment of the market. This is attributed to ability of test to provide reliable analysis of sperm DNA integrity. As DNA fragmentation in sperm cells is a leading cause of infertility in males, there is growing adoption of this test, which is likely to drive the growth during the forecast period.

Semen analysis was the most preferred test and used as a primary test for the diagnosis. This can be done through microscopic examination and the latest method is CASA. Although microscopic examination accounted for more share as compared to CASA in 2016, CASA is expected to replace the microscopic method during the forecast period.

Oxidative stress test analysis was the second largest segment by revenue in 2016 due to increasing usage. Other tests for diagnosis include sperm viability testing and sperm proteomics.

Treatment Insights

Medications and ART are the treatments considered during the market estimation. The best choice to treat an infertile male for a natural pregnancy is to enhance spermatogenesis by hormonal therapy. However, the treatment is effective only in patient with low sperm count.

ART is used to treat major male factors responsible for male infertility, such as sperm autoantibodies, viral orchitis, epididymal dysfunction, accessory gland infection, chemotherapy, heat, trauma, and other idiopathic factors. High cost of treatment and requirement of number of therapy cycles are the major factors that help generate highest revenue in the market.

Global male infertility market by treatment, 2016 (%)

Global male infertility Market

Increasing healthcare expenditure in developing countries, growing awareness about male infertility, and rising adoption in middle- and low-income countries are the other factors that are anticipated to drive the ART segment during the forecast period from 2017 to 2025.

Regional Insights

Asia Pacific is expected to grow at a rapid rate over the forecast period. Emerging countries in the region, including India, China, and Singapore have been experiencing strong economic growth. Increasing geriatric population, rising smoking, and lifestyle-associated diseases have resulted in increased incidence of male infertility in the region.

Europe dominated the market, which accounted for more than 30.0% of the total market in 2016. Availability of well-equipped and advanced fertility clinics, higher adoption of costlier treatment, better coverage for diagnosis & treatment, and high awareness levels are the factors responsible for the dominance of the region.

Competitive Insights

The global market is highly competitive in nature. However, EMD Sereno, Inc. was one of the dominating players in 2016. Some other key industry participants include Andrology solutions; Aytu BioScience, Inc.; Bayer Healthcare; Cadila Healthcare Ltd.; EMD Sereno, Inc.; Halotech DNA SL; Intas pharmaceuticals Ltd.; and SCSA diagnostics, Inc.

Development of innovative technologies for diagnosis & treatment, acquisitions, and partnerships or collaborations for development & commercialization of products are expected to be key parameters to remain competitive and gain market share.

Report Scope



Base year for estimation


Actual estimates/Historical data

2014 - 2016

Forecast period

2017 - 2025

Market representation                                                 

Revenue in USD Million and CAGR from 2017 to 2025

Regional scope

North America, Europe, Asia Pacific, Central & South America, Middle East & Africa

Country scope

U.S., Canada, Germany, U.K., China, Japan, Brazil, Mexico, South Africa

Report coverage             

Revenue forecast, competitive landscape, growth factors and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Segments Covered in the Report

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global male infertility market on the basis of test, treatment, and region:

  • Test Outlook (Revenue, USD Million, 2014 - 2025)

    • DNA Fragmentation Technique

    • Oxidative Stress Analysis

    • Microscopic Examination

    • Sperm Agglutination

    • Computer-Assisted Semen Analysis

    • Sperm Penetration Assay

    • Others

  • Treatment Outlook (Revenue, USD Million, 2014 - 2025)

    • Assisted Reproductive Technology

    • Medication

  • Regional Outlook (Revenue, USD Million, 2014 - 2025)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

    • Asia Pacific

      • China

      • Japan

    • Central & South America

      • Brazil

      • Mexico

    • Middle East & Africa

      • South Africa

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $5,950
Multi User (2-5) - $6,950
Enterprise Access - $8,950

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified